The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company has a price-to-book ratio of 28.0.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 26.3 | 59.17% |
2022-12-31 | 16.5 | 6.61% |
2021-12-31 | 15.5 | 7.36% |
2020-12-31 | 14.4 | -190.14% |
2019-12-31 | -16.0 | -0.73% |
2018-12-31 | -16.1 | -153.29% |
2017-12-31 | 30.3 | 37.99% |
2016-12-31 | 22.0 | -9.2% |
2015-12-31 | 24.2 | -59.56% |
2014-12-31 | 59.8 | 220.35% |
2013-12-31 | 18.7 | 16.28% |
2012-12-31 | 16.0 | |
2011-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Pfizer PFE | 1.61 | -94.26% | ๐บ๐ธ USA |
Eli Lilly LLY | 65.3 | 132.81% | ๐บ๐ธ USA |
Amgen AMGN | 22.6 | -19.42% | ๐บ๐ธ USA |
Biogen BIIB | 1.87 | -93.33% | ๐บ๐ธ USA |
Gilead Sciences GILD | 3.63 | -87.07% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 3.32 | -88.16% | ๐บ๐ธ USA |
AstraZeneca AZN | 5.41 | -80.70% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | 4.99 | -82.22% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | 5.97 | -78.70% | ๐บ๐ธ USA |